Tirzepatide: Research Overview, Mechanisms, and Current Evidence
Tirzepatide is a dual agonist that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is approved by the US FDA as a prescription drug for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), given as a once-weekly subcutaneous injection. Because it is a prescription drug, the framing here is research-use only. The information below summarizes published research for educational and research purposes only. It is not medical advice and is not guidance for use in humans.
Tirzepatide is a prescription drug. Available for research use from our preferred vendor, Project Zero. For laboratory research use only.
How It Works (Preclinical Mechanisms)
Tirzepatide combines activity at two incretin receptors, GIP and GLP-1, in a single molecule, which is reported to enhance its metabolic effects.
- Activates both GIP and GLP-1 receptors, an approach reported to act on complementary metabolic pathways.
- Enhances glucose-dependent insulin secretion and improves blood sugar control.
- Reported to reduce appetite and food intake, contributing to substantial weight loss.
- Studied for improvements in cardiometabolic measures such as blood pressure and lipids alongside weight reduction.
Areas of Research Interest
Published studies have examined tirzepatide across diabetes and obesity in the large SURPASS and SURMOUNT trial programs.
Chronic weight management
Studied in the Phase III SURMOUNT program, with weight reductions among the largest reported for a drug.
Type 2 diabetes
Studied in the SURPASS program for glycemic control versus placebo, semaglutide, and insulin.
Cardiometabolic comorbidities
Examined for effects on sleep apnea and cardiovascular risk factors associated with excess weight.
Comparative effectiveness
Compared head-to-head with semaglutide in the SURMOUNT-5 weight-management trial.
Reported Study Parameters
For laboratory research use only. The table below reports the doses and routes used in published clinical trials and approved labeling, with sources. It describes what was administered in those studies and is not a protocol, recommendation, or guidance for use in humans or animals. Because tirzepatide is a prescription drug, this information is provided for research context only.
| Research Model | Dose and Route Reported | Source |
|---|---|---|
| Adults with obesity (Phase III SURMOUNT-1) | Once-weekly subcutaneous tirzepatide 5, 10, or 15 mg for 72 weeks | Jastreboff 2022·DOI |
| Obesity or overweight, with and without diabetes (SURMOUNT-1 to -4) | Once-weekly subcutaneous tirzepatide; gastrointestinal tolerability analyzed across the program | Rubino 2025·DOI |
| Human research (regulatory status) | FDA-approved as tirzepatide (Mounjaro for type 2 diabetes; Zepbound for chronic weight management); a prescription drug provided here for research use only | Johansson 2026·DOI |
Products are supplied as lyophilized powder requiring reconstitution. For reconstitution concentration math, use the Peptide Calculator.
Latest Research (2022 to 2026)
Peer-reviewed literature indexed on PubMed documents the large SURMOUNT and SURPASS trial programs and comparative studies of tirzepatide.
SURMOUNT-1 (weight reduction)
A 2022 Phase III trial in 2,539 adults with obesity reported mean weight reductions of 15.0%, 19.5%, and 20.9% with tirzepatide 5, 10, and 15 mg once weekly over 72 weeks, versus 3.1% with placebo, with mostly mild to moderate gastrointestinal side effects. PubMed·DOI
Gastrointestinal tolerability (SURMOUNT-1 to -4)
A 2025 analysis across the SURMOUNT program reported that most gastrointestinal adverse events were non-serious and occurred during dose escalation, and that weight reduction was similar whether or not participants experienced nausea. PubMed·DOI
Head-to-head with semaglutide (SURMOUNT-5)
A 2026 analysis using head-to-head SURMOUNT-5 Phase III data modeled long-term outcomes of tirzepatide versus semaglutide at maximum tolerated doses for weight management in adults without type 2 diabetes. PubMed·DOI
SURPASS and SURMOUNT overview
A 2024 review summarized the SURPASS diabetes trials and SURMOUNT obesity trials, describing dose-dependent reductions in HbA1c and body weight at 5, 10, and 15 mg, and noting ongoing cardiovascular outcome trials. PubMed
Research Questions
What is tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Combining two incretin pathways is reported to enhance its effects.
What is the current state of human evidence?
The SURPASS and SURMOUNT Phase III programs established large effects on weight and blood sugar, including weight reductions among the largest reported for a drug. Cardiovascular outcome trials are ongoing.
What does the available safety literature suggest?
Common adverse effects are gastrointestinal (nausea, vomiting, diarrhea), mostly mild to moderate and occurring during dose escalation. It carries specific warnings, so it should be used only under medical supervision.
Referenced Citations
Literature indexed on PubMed.
- Jastreboff, A.M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med., 387(3), 205-216. PubMed·DOI
- Rubino, D.M., et al. (2025). Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes Obes. Metab., 27(4), 1826-1835. PubMed·DOI
- Johansson, E., et al. (2026). Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial. J. Med. Econ., 29(1), 1258-1278. PubMed·DOI
- Scheen, A. (2024). Tirzepatide: overview of clinical studies SURPASS in type 2 diabetes and SURMOUNT in obesity. Rev. Med. Liege, 79(12), 812-820. PubMed
PeptideInfo.org provides information strictly for educational and research purposes. All referenced products are intended for laboratory and research use only and are not approved for human consumption, medical use, or self-administration. Nothing on this page constitutes medical advice. Research summaries reference literature indexed on PubMed.